RADIOLABELLED GRPR-ANTAGONIST FOR USE AS THERAGNOSTIC

The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting pharmaceuticals and their use in a theragnostic approach for selection and therapy of subjects with GRPR-expressing malignancies. In particular, the present disclosure relates to a pharmaceutical composition of a r...

Full description

Saved in:
Bibliographic Details
Main Authors WEGENER, Antje, ORLANDI, Francesca, MARIANI, Maurizio F, CHICCO, Daniela
Format Patent
LanguageEnglish
Published 12.10.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present disclosure relates to gastrin-releasing peptide receptor (GRPR) targeting pharmaceuticals and their use in a theragnostic approach for selection and therapy of subjects with GRPR-expressing malignancies. In particular, the present disclosure relates to a pharmaceutical composition of a radiolabeled GRPR-antagonist, for use in treating GRPR-positive tumors in a human subject selected for said treatment, wherein said subject has been selected for the treatment by PET/CT or PET/MRI imaging with a corresponding 68Ga-labelled GRPR antagonist as contrast agent.
Bibliography:Application Number: US202017754059